Clinical trials · New York, NY
Advanced or Metastatic Solid Tumors clinical trials in New York
We’re tracking 615 recruiting advanced or metastatic solid tumors studies with a site in or near New York — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT06641908RecruitingPhase 1
M3554 for advanced solid tumors
This trial tests a new drug, M3554, that targets a protein called GD2 found on some cancer cells. It is for people with advanced soft tissue sarcoma or glioblastoma that has stopped responding to standard treatments. The goal is to see if M3554 is safe and can shrink tumors.
New York, New YorkAges 18 years+ - NCT06638307RecruitingPhase 1
Study of new drug MEN2312 for advanced breast cancer with specific genetic changes
This trial tests a new drug, MEN2312, for people with advanced breast cancer that has specific genetic changes in PIK3CA, AKT1, or PTEN. It's for those who have already tried certain hormone therapies and a CDK4/6 inhibitor combination, and the cancer has continued to grow.
New York, New YorkAges 18 years+ - NCT04577014RecruitingPhase 1/Phase 2
Retifanlimab plus chemotherapy for advanced soft tissue sarcoma
This trial tests retifanlimab (an immunotherapy that helps your immune system recognize cancer) combined with gemcitabine and docetaxel chemotherapy. It’s for people with advanced soft tissue sarcoma that can’t be safely removed with surgery, aiming to shrink tumors and improve outcomes.
New York, New YorkAges 18 years+ - NCT07193511RecruitingPhase 1/Phase 2
A new drug for advanced bladder and other solid tumors
This trial tests a new drug, AVZO-103, alone or with other treatments, for people with advanced bladder cancer or certain other solid tumors. It aims to find out if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT06031688RecruitingPhase 2
Targeted treatment for lung cancer with a MET gene change
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
New York, New YorkAges 18 minutes+ - NCT07189403RecruitingPhase 1
Study of DS9051b for adrenal cancer and prostate cancer
This trial tests a new drug called DS9051b in people with advanced adrenal cancer or metastatic prostate cancer that has stopped responding to other treatments. It aims to see if the drug is safe and works against these cancers.
New York, New YorkAges 18 years+ - NCT06246968RecruitingPhase 1
Pembrolizumab and Cryoablation for Breast Cancer
This trial is testing a combination of a freezing procedure (cryoablation) and an immunotherapy drug called pembrolizumab (Keytruda) for people with triple-negative breast cancer that has spread. The goal is to see if freezing the tumor helps the immune system fight the cancer better.
New York, New YorkAges 18 years+ - NCT07069712RecruitingPhase 2
New drug combinations before and after surgery for stomach or esophageal cancer
This study tests new drug combinations given before and after surgery for people with stomach or gastroesophageal cancer that can be removed but is locally advanced (has grown into nearby tissue). The goal is to see if these combinations can shrink the tumor and improve outcomes.
New York, New YorkAges 18 years+ - NCT06892548RecruitingPhase 1/Phase 2
Combination therapy for advanced lung cancer
This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.
New York, New YorkAges 18 years+ - NCT06064877RecruitingPhase 3
Study of ficlatuzumab plus cetuximab for advanced head and neck cancer
This trial tests a combination of two drugs, ficlatuzumab and cetuximab, for people with recurrent or metastatic head and neck cancer that is HPV-negative and has not responded to prior immunotherapy and chemotherapy. It aims to see if this combination can help shrink tumors or slow the disease.
New York, New YorkAges 18 years+ - NCT05440708RecruitingPhase 1/Phase 2
Study drug for advanced liver cancer that cannot be removed
This trial tests TTI-101, by itself and with other cancer medicines, for liver cancer that is advanced and cannot be removed by surgery. It aims to see whether the treatment can slow the cancer down and improve outcomes.
New York, New YorkAges 18 years+ - NCT06655376RecruitingPhase 4
Aspirin study for advanced heart failure with a heart pump
This trial tests if taking aspirin along with a standard blood thinner helps people with a HeartMate3 heart pump have fewer bleeding or clotting problems. It is for people who have had their pump for at least 3 months.
New York, New YorkAges 18 years+ - NCT07186842RecruitingPhase 1/Phase 2
Testing the safety of BNT329 for advanced CA19-9 positive tumors
This trial tests if the investigational drug BNT329 is safe and could help people with advanced solid tumors that make a marker called CA19-9. It is for those who have tried standard treatments and need new options.
New York, New YorkAges 18 years+ - NCT07228247RecruitingPhase 1/Phase 2
Study of HMPL-A251 for advanced HER2-positive cancers
This study tests an experimental drug (HMPL-A251) for people with advanced solid tumors that have the HER2 protein. It aims to see if the drug can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
New York, New YorkAges 18 years+ - NCT05433142RecruitingPhase 1
XmAb 819 for advanced kidney cancer and other solid tumors
This Phase 1 trial tests a new drug called XmAb 819 to treat advanced clear cell kidney cancer and other cancers that have grown despite standard treatments. It mainly looks at safety and how the body responds, with the goal of finding signs the drug can work.
New York, New YorkAges 18 years+ - NCT06463340RecruitingPhase 1
Study of SGR-3515 for advanced solid tumors
This trial tests a new drug called SGR-3515 for people with advanced solid tumors. It aims to see if the drug is safe and how it works in the body.
New York, New YorkAges 18 years+ - NCT06657144RecruitingPhase 1
Study of CHS-114 and toripalimab for advanced solid tumors
This study tests a new drug combo (CHS-114 + toripalimab) for people with advanced solid tumors like stomach, esophageal, or colorectal cancer that have already been treated. It aims to see if adding these drugs can help control the cancer better.
New York, New YorkAges 18 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
New York, New YorkAges 18 years+ - NCT05307705RecruitingPhase 1
Testing LOXO-783 for PIK3CA-mutated cancers
This trial tests an experimental drug (LOXO-783) for people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The goal is to see if the drug can shrink or slow the growth of the cancer.
New York, New YorkAges 18 years+ - NCT06545942RecruitingPhase 1
Studying MOMA-313 for advanced or metastatic solid tumors
This trial tests a new oral drug, MOMA-313, alone or with another drug (olaparib), in people whose cancer has a specific DNA repair problem (HR-deficient mutation). It aims to see if the drug can shrink tumors or slow their growth.
New York, New YorkAges 18 years+ - NCT06311214RecruitingPhase 2
Personalized ADC therapy for advanced solid tumors
This trial tests personalized antibody-drug conjugates (ADCs) for advanced solid tumors. It looks for specific proteins on your tumor cells to match you with a treatment that targets them directly.
New York, New YorkAges 18 years+ - NCT07721792Recruiting
Study on advanced braces for leg injuries
This study tests a new type of leg brace for people who currently use an ankle-foot orthosis (AFO) to help with walking or daily activities after a lower leg injury. The goal is to see if the new brace works better and is more comfortable.
New York, New YorkAges 18–80 - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
New York, New YorkAges 1–30
Hear when a new Advanced or Metastatic Solid Tumors trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Memorial Sloan Kettering Cancer Center · 12 studies
- Columbia University Irving Medical Center · 4 studies
- Icahn School of Medicine at Mount Sinai · 2 studies
- Memorial Sloan Kettering Basking Ridge · 2 studies
- Memorial Sloan Kettering Bergen · 2 studies
- Memorial Sloan Kettering Commack · 2 studies
- Memorial Sloan Kettering Monmouth · 2 studies
- Memorial Sloan Kettering Nassau · 2 studies
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in New York.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near New York?
- Yes. We're currently tracking 615 recruiting advanced or metastatic solid tumors studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.